#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting

InvestigationalNo placebo

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Golimumab

Contact Research Centre

Migraine

Recruiting

Registered drug

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

Contact Research Centre

Migraine

Recruiting

Registered drug

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide

Contact Research Centre

Acute myocardial infarction

Recruiting

Registered drugNo placebo

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Colchicine

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

Investigational

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Bio89-100

Contact Research Centre

Acute myocardial infarction

Recruiting

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Selatogrel

Contact Research Centre

Coeliac disease

Recruiting

Investigational

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate

Contact Research Centre

Colitis ulcerative

Recruiting

InvestigationalNo placebo

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Golimumab

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Azd5004

Contact Research Centre

Arteriosclerosis coronary artery+2

Recruiting

Registered drugNo placebo

Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bempedoic Acid

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Austria

Participants:18–64 years · 65+ years

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.